Evoke Pharma amends Series B/C warrants to accelerate vesting, allow pre-funded warrants

Evoke Pharma Inc

Series C warrants become exercisable for up to 3x Series B shares exercised before March 27, 2024 deadline.
After deadline, remaining Series B exercises trigger one-for-one vesting of Series C warrants.
Holders may elect pre-funded warrants at exercise price of $0.6799 per share instead of common stock.
No change to total number of warrant shares underlying each series.
Company will allow other holders to enter identical amendment.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Evoke Pharma Inc amended Warrant Amendment with certain holders of its outstanding Series A Warrants, Series B Warrants, and Series C Warrants (effective 2024-03-25).

Action: amendment
Counterparty: certain holders of its outstanding Series A Warrants, Series B Warrants, and Series C Warrants
Effective: 2024-03-25

Exact text from the filing

On March 25, 2024, Evoke Pharma, Inc. (the “Company”) entered into an amendment (the “Warrant Amendment”) with certain holders (each, a “Holder”) of its outstanding Series A Warrants to purchase shares of common stock (the “Series A Warrants”), Series B Warrants to purchase shares of common stock (the “Series B Warrants”), and Series C Warrants to purchase shares of common stock (the “Series C Warrants”).

View on SEC.gov

545 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0000950170-24-035987

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.